Eli Lilly & Co, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Courtney Breen from Bernstein maintained a Buy rating on the stock and has a $1,100.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Courtney Breen has given his Buy rating due to a combination of factors that highlight Eli Lilly & Co’s promising prospects. The recent conference reaffirmed the company’s data expectations, particularly in the context of their obesity treatment, Orfo. Discussions with key opinion leaders in the field have underscored the importance of tailoring treatments to patient needs, which aligns well with Eli Lilly’s approach.
Moreover, the Orfo ATTAIN-1 study results were positively received, indicating that the treatment is likely to be a significant option for many patients. The study’s design, which included more relaxed dietary guidelines, was seen as practical and favorable. Additionally, the Orfo ACHIEVE-3 data, although not presented at the conference, showed strong results when compared to competitors, further supporting the company’s potential for growth. These insights contribute to Breen’s confidence in Eli Lilly’s future performance, justifying the Buy rating.